An interventional study of Genetic analysis of NLRP3 and Circadian rhythm measurement in Cryopyrin Associated Periodic Syndrome, Familial Cold Urticaria and Muckle-Wells Syndrome, sponsored by Hospices Civils de Lyon. Recruiting at 6 sites in France. Open to participants aged 6 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-27.
Sponsored by Hospices Civils de Lyon · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Cryopyrin-Associated Periodic Syndromes with a site in France — 2 open to participants now, 2 under way, none of them phase 3. Cryopyrin-Associated Periodic Syndromes · France.
Among the 10 studies in Cryopyrin-Associated Periodic Syndromes with a site in France, this one is the only one that started in 2026, is the only one with no phase, and was the 10th registered.
35 studies on the registry are indexed under Cryopyrin-Associated Periodic Syndromes; 5 are open to participants now.
Browse Cryopyrin-Associated Periodic Syndromes studies →2 of the 10 studies in Cryopyrin-Associated Periodic Syndromes with a site in France are open now. Recruiting first, the newest first:
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 4 Cryopyrin-Associated Periodic Syndromes studies recruiting now, 1 sets no upper age limit and none stop at 75 or younger; 3 take children under 18; 2 take healthy volunteers.
This study: 6 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 1 started in 2026.
This study's planned enrollment of 30 is above the median of 19 across 27 interventional studies indexed under Cryopyrin-Associated Periodic Syndromes.
Median enrollment 31 across the 8 interventional studies, 322 across the 2 observational. Of the 8 that completed or were terminated, 6 (75%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 10 have an industry lead sponsor. The 5 most frequent:
Hospices Civils de Lyon is the lead sponsor of 1,868 studies on the registry; 447 are open to participants now.
Hospices Civils de Lyon has 1 study filed under Cryopyrin-Associated Periodic Syndromes — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 10 studies in Cryopyrin-Associated Periodic Syndromes with a site in France, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Circadian rhythms are characterized by the physiology's adaptation to the alternation of day and night, enabling to adapt to the environment. These rhythms are generated by a molecular clock within each cell. At the molecular level, the circadian clock is based on a complex system of cell-autonomous transcription loops. These exert positive and negative feedback on themselves, generating cyclic transcriptional activity.
Recent studies suggest that many aspects of innate immunity are controlled by circadian rhythm through inhibition of NLRP3 inflammasome activation. Nevertheless, the regulation of the NLRP3 inflammasome by the circadian clock has yet to be elucidated. Inflammasomes are molecular platforms that control caspase-1 activation and consequently the maturation of precursors of (interleukine) IL-1β, pro-IL-18, a pro-inflammatory cytokine. Since its discovery, its functions have been widely characterized as part of the innate immune response as a sensor of pathogens and danger signals (extracellular ATP (Adenosine triphosphate), atmospheric pollutants). NLRP3 (nucleotide-binding domain LRR (leucin-rich repeat ) and pyrin-containing receptor 3) has been described for its genetic association with dominant monogenic hereditary syndromes characterized by recurrent systemic inflammatory episodes in the absence of any infection or autoimmune disease, known as CAPS (cryopyrin-associated periodic syndrome) or cryopyrinopathies which is a continuum of diseases ranging from a moderate to the most severe form of the syndrome: familial cold urticaria syndrome, Muckle-Wells syndrome (MWS), and CINCA/NOMID syndrome.
Interestingly, patients with Muckle-Wells syndrome show a circadian pattern of symptoms, with a recurrent, predominantly vesperal fever peak lasting a few hours, and extreme fatigue on a daily basis. However, a molecular link between the circadian clock and CAPS pathology remains to be determined.
The aim of this protocol is to identify circadian rhythm dysregulation in patients with CAPS confirmed by genetic analysis of NLRP3, to demonstrate a link between circadian clock and CAPS syndrome, and to identify circadian clock regulatory pathways.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patient with CAPS group :
Control group (healthy participant):
Patient with CAPS group :
Control group (healthy participant):
Confirmed by genetic analysis of NLRP3
Genetic: Genetic analysis of NLRP3 · Device: Circadian rhythm measurement · Biological: Saliva sampling · Other: Questionnaire · Other: AIDAI score · Biological: Blood sampling
Healthy participant (absence of CAPS, verified by NLRP3 gene analysis) living in the same household as a CAPS participant included in the protocol
Genetic: Genetic analysis of NLRP3 · Device: Circadian rhythm measurement · Biological: Saliva sampling · Other: Questionnaire · Biological: Blood sampling
Blood test for genetic analysis of NLRP3
Wear a Withings Pulse HR (heart rate) actigraphic watch 24 hours a day for 1 month to define circadian rhythm
Saliva sampling for salivary melatonin determination
Questionnaire to determine chronotype
Disease activity score using AIDAI score (only for patients in the CAPS group) AIDAI : AUTO-INFLAMMATORY DISEASE ACTIVITY INDEX
1. Inflammatory cytokines measurement : IL1-beta (Interleukin-1) and IL-18. 2. Molecular characterization of circadian clock signaling pathways
Description of circadian rhythm deregulation in patients with cryopyrinopathy (CAPS) whose diagnosis was confirmed by genetic analysis of NLRP3,
Concentration of the peak secretion of melatonin in both arms
Time frame: 6 months after inclusion
Description of circadian rhythm deregulation in patients with cryopyrinopathy (CAPS) whose diagnosis was confirmed by genetic analysis of NLRP3,
Concentration of the peak secretion of melatonin in both arms
Time frame: 12 months after inclusion
Description of circadian rhythm deregulation in patients with cryopyrinopathy (CAPS) whose diagnosis was confirmed by genetic analysis of NLRP3,
time of the peak secretion of melatonin in both arms
Time frame: 6 months after inclusion
Description of circadian rhythm deregulation in patients with cryopyrinopathy (CAPS) whose diagnosis was confirmed by genetic analysis of NLRP3,
time of the peak secretion of melatonin in both arms
Time frame: 12 months after inclusion
Difference in circadian clock biomarkers between patients and control participants for Circadian Rhythm Characteristics.
Determination of circadian rhythms : amplitude in both arms
Time frame: 6 th month
Difference in circadian clock biomarkers between patients and control participants for Circadian Rhythm Characteristics.
Determination of circadian rhythms : period in both arms
Time frame: 6 th month
Difference in circadian clock biomarkers between patients and control participants for Circadian Rhythm Characteristics.
Determination of circadian rhythms : phase in both arms
Time frame: 6 th month
Chronotype determination
Number of patients in each chronotype for the 2 arms based on the specific questionnaire in both arm
Time frame: 6 th month
sleep duration
sleep duration in both arms
Time frame: 6 th month
number of steps
Daily activity in both arms
Time frame: 6 th month
Comparison of inflammatory state
basal levels of IL1β in patient monocytes in both arms
Time frame: 6 months after inclusion
Comparison of inflammatory state
basal levels of IL1β in patient monocytes in both arms
Time frame: 12 months after inclusion
Comparison of inflammatory state
basal levels of IL18 in patient monocytes in both arms
Time frame: 6 months after inclusion
Comparison of inflammatory state
basal levels of IL18 in patient monocytes in both arms
Time frame: 12 months after inclusion
Disease activity measurement
Number of patient with active disease ie AIDAI (AUTO-INFLAMMATORY DISEASE ACTIVITY INDEX) score \>9 in CAPS patient arm
Time frame: 6 months after inclusion
Disease activity measurement
Number of patient with active disease ie AIDAI (AUTO-INFLAMMATORY DISEASE ACTIVITY INDEX) score \>9 in CAPS patient arm
Time frame: 12 months after inclusion
presence or absence of an abnormality in the NLRP3 signalling pathway in CAPS arm compared control arm
Biochemical characterization of the NLRP3 inflammasome protein regulatory pathway in both arms
Time frame: 6 months after inclusion
presence or absence of an abnormality in the NLRP3 signalling pathway in CAPS arm compared to control arm
Biochemical characterization of the NLRP3 inflammasome protein regulatory pathway in both arms
Time frame: 12 months after inclusion
presence or absence of ASC inflammasome protein regulatory pathway in CAPs arm compared to control arm
Biochemical characterization of the ASC inflammasome protein regulatory pathway in both arms
Time frame: 6 months after inclusion
presence or absence of ASC inflammasome protein regulatory pathway in CAPS arm compared to control arm
Biochemical characterization of the ASC inflammasome protein regulatory pathway in both arms
Time frame: 12 months after inclusion
presence or absence of the CASPASE-1 inflammasome protein regulatory pathway in CAPS arm compared to control arm
Biochemical characterization of the CASPASE-1 inflammasome protein regulatory pathway in both arms
Time frame: 6 months after inclusion
presence or absence of the CASPASE-1 inflammasome protein regulatory pathway in CAPS arm compared to control arm
Biochemical characterization of the CASPASE-1 inflammasome protein regulatory pathway in both arms
Time frame: 12 months after inclusion
presence or absence of REV-ERBα inflammasome protein regulatory pathway in CAPS arm compared to control arm
Biochemical characterization of the REV-ERBα inflammasome protein regulatory pathway in both arms
Time frame: 6 months after inclusion
presence or absence of REV-ERBα inflammasome protein regulatory pathway in CAPS arm compared to control arm
Biochemical characterization of the REV-ERBα inflammasome protein regulatory pathway in both arms
Time frame: 12 months after inclusion
Plan to share: No
No publications or documents are linked to this record.
Started Feb 2026 (actual). Primary completion is estimated for Feb 2029, 36 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Cryopyrin-Associated Periodic Syndromes →